Kyntra Bio Appointed Singer to Board
The biotech firm announced a leadership change involving Andrew E. Singer and outgoing member Maykin Ho.
Updated on Oct. 1, 2026 in People
Kyntra Bio has appointed Andrew E. Singer to its Board of Directors and Audit Committee. Singer takes the seat following the resignation of long-time board member Maykin Ho.
Why it matters
The board transition introduces a new director with significant financial advisory experience to the company's oversight team. This shift concludes the eight-year tenure of the previous director.
Andrew E. Singer brings 25 years of professional experience to the board, having previously advised on $50 billion worth of transactions.
The players
Andrew E. Singer
He is the CEO of Fika Bio Consulting and a former executive at major financial institutions including Credit Suisse and Wells Fargo.
Maykin Ho
She is a former member of the Kyntra Bio Board of Directors who concluded her eight-year service with the company.
Kyntra Bio
This San Francisco-based biotechnology company focuses on clinical development and research.
The details
Andrew E. Singer currently serves as the CEO of Fika Bio Consulting and previously held positions at RBC Capital Markets, Wells Fargo, and Credit Suisse. His appointment to the Kyntra Bio board and its Audit Committee marks the primary leadership update for the San Francisco-based firm.
Timeline
Maykin Ho stepped down from the Board of Directors on September 30, 2026.
Andrew E. Singer joined the Board of Directors on October 1, 2026.
Market Landscape
The appointment aligns with the broader industry trend of strengthening board audit committees with individuals possessing deep financial and transactional expertise. This move positions Kyntra Bio to leverage external consulting experience as it manages its long-term corporate governance strategy.
The board transition does not immediately impact product pricing or consumer services for the average client. It represents an internal governance shift intended to stabilize the company's long-term financial oversight.
The takeaway
Board transitions are a standard part of the corporate lifecycle as firms seek new expertise to navigate future challenges. Investors and stakeholders should monitor public filings for any shifts in corporate strategy resulting from the new appointment.
Further reading
For more on local leadership changes, visit People.
